Event info
Date:24 Oct
Time:9:00 - 14:00
Venue:Medicon Valley Alliance, Copenhagen S

NDA HTA Seminar – The future of Health Technology Assessment in Europe

On the 24th October NDA Group invites you and your colleagues in the market access department/HEOR to a complimentary seminar on the future of HTA.

The market access environment is getting increasingly challenging. The ability to develop plans and strategies for access, for today as well as tomorrow, is critical to bring new medicines to patients.

With 17 years as Executive Director for NICE, Carole Longson has unparalleled experience in understanding how HTA bodies work and collaborate in the EU. In June 2018 she joined NDA as a HTA Advisor.

This seminar will discuss the past, present and future of HTA and market access. On stage Carole is joined by an esteemed panel comprising Dr Steffen Thirstrup, former Division Head at the Danish Medicines Agency and CHMP member, Dr Fredrik Andersson, Senior Director Global HEOR Ferring and Mark Aagren, Senior Director Market Access and Public Affairs ALK.

Date: 24 October 2018
Time: 8:30 – 12:00
Venue: Medicon Valley Alliance, Arne Jacobsens Alle 15 , 2300 Ørestad City, Copenhagen, Denmark, Ground floor




Registration & light breakfast


Claes Buxfeldt, HTA Director, NDA Advisory Services Ltd

Session 1 – Challenges on development programs for new drugs
Professor Steffen Thirstrup, Director, NDA Regulatory Advisory Board (previous Danish Medicines Agency / EMA)

  • Clinical trial guidelines and how to deliver patient centric critical data for regulatory and HTA bodies. Implications and mitigations.

Session 2 – HTA alignment in Europe – what does the future of HTA have in store?
Professor Carole Longson, Life Science Policy, Research and Market Access, NDA Advisory Services Ltd (previous executive Director NICE UK)

Conversation leaders at stage:
Claes Buxfeldt, HTA Director, NDA Advisory Services Ltd
Steffen Thirstrup, Director, NDA Regulatory Advisory Board, NDA Advisory Services Ltd
Dr Fredrik Andersson, Senior Dir Global HEOR Ferring
Mark Aagren, Senior Director Market Access and Public Affairs ALK

  • EU clinical effectiveness review (Parliaments proposal), where is it going? Will EU get a ‘super-HTA body’ in the future?

  • EUnetHTA and EMA, directions and implications for future collaborations

  • NICE after Brexit?


End of meeting – conclusions and take-home messages
Claes Buxfeldt, HTA Director, NDA Advisory Services Ltd

12:00 – 1400

Ask the Experts
Book a 20 min slot for a chat directly with our Experts by contacting rachel.stonebridge@ndareg.com

About NDA Group
NDA Group is a world leading drug development consultancy. Over the past five years NDA has supported over 40% of the new medicinal products approved in Europe.


Steffen Thirstrup
Director, NDA Regulatory Advisory Board
NDA Advisory Services Ltd

Carole Longson
Life Science Policy, Research and Market Access
NDA Advisory Services Ltd

 Claes Buxfeldt
HTA Director
NDA Advisory Services Ltd

Organized by:

In collaboration with: